Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small ce...
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2006-03-30
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 218
- Registration Number
- NCT00308750
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States
A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-02-28
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 165
- Registration Number
- NCT00297089
- Locations
- 🇺🇸
Site Reference ID/Investigator# 3353, Chicago, Illinois, United States
🇺🇸Site Reference ID/Investigator# 6006, Philadelphia, Pennsylvania, United States
🇺🇸Site Reference ID/Investigator# 2411, Fort Lauderdale, Florida, United States
Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
- First Posted Date
- 2006-02-23
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 53
- Registration Number
- NCT00295503
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Pemetrexed Chemotherapy in Poor-Risk Patients With Advanced Head and Neck Cancer
- First Posted Date
- 2006-02-17
- Last Posted Date
- 2020-02-10
- Target Recruit Count
- 5
- Registration Number
- NCT00293579
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
Trial of Cetuximab and Pemetrexed With Radiation in Head and Neck Cancer
- Conditions
- First Posted Date
- 2006-02-14
- Last Posted Date
- 2013-05-06
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 40
- Registration Number
- NCT00291707
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy
- Conditions
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2007-06-08
- Lead Sponsor
- Point Therapeutics
- Target Recruit Count
- 400
- Registration Number
- NCT00290017
- Locations
- 🇺🇸
Texas Cancer Center (Dallas Southwest), Dallas, Texas, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
🇺🇸Oncology/Hematology Care, Inc., Cincinnati, Ohio, United States
Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2020-03-05
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 31
- Registration Number
- NCT00276783
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸Hematology-Oncology Associates of Illinois, Chicago, Illinois, United States
Feasibility Study of Pemetrexed in Combination With Cisplatin or Carboplatin as Adjuvant Treatment of Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-12-23
- Last Posted Date
- 2015-08-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 122
- Registration Number
- NCT00269152
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santiago De Compostela, Spain
Radiation Therapy, Pemetrexed Disodium, and Carboplatin in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2005-12-22
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 27
- Registration Number
- NCT00268437
- Locations
- 🇺🇸
Rush-Copley Cancer Care Center, Aurora, Illinois, United States
🇺🇸Graham Hospital, Canton, Illinois, United States
🇺🇸Mason District Hospital, Havana, Illinois, United States
S0526: Pemetrexed Disodium in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2012-11-01
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 27
- Registration Number
- NCT00265785
- Locations
- 🇺🇸
NEA Medical Center - Stadium Boulevard, Jonesboro, Arkansas, United States
🇺🇸CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States
🇺🇸St. John's Regional Health Center, Springfield, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.